Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stellar Pharmaceuticals and Watson Pharmaceuticals have decided to suspend their supply and licensing related to Uracyst (sodium chondroitin sulfate solution 2.0%) as a treatment for interstitial cystitis.
Subscribe to our email newsletter
Uracyst is a fluid that is instilled into the bladder.
It contains Sterile Sodium Chondroitin Sulfate Solution, 2.0%, and is indicated for reducing the symptoms of painful bladder syndrome/interstitial cystitis (PBS/IC).
The suspension of the agreement entitles Watson Pharma to receive a royalty on net sales of Uracyst from Stellar in the US over the life of certain Uracyst patents.
Stellar intends to seek a new product sponsor for Uracyst in the US.
Watson acquired the rights to develop and commercialize Uracyst in the US in December 2006.
In November 2010, based on the results of a US pilot test study evaluating Uracyst, Watson said it did not plan to allocate any additional resources to further pursue the product development program.